2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) has announced positive topline results from the SURMOUNT-1 study, a 176-week trial, which is the longest completed study of... ByInvesting.com • 20 Aug ...

Indianapolis: Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's ...

Eli Lilly said it received Food and Drug Administration ... is now approved to treat two types of inflammatory bowel disease in the U.S., the Indianapolis company said Wednesday.

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $672 billion and impressive revenue growth of 27% in the past year, has received U.S. Food ...

The FDA ap­proved Eli Lil­ly’s Omvoh in Crohn’s dis­ease, the com­pa­ny an­nounced Wednes­day, hand­ing the drug its sec­ond in­di­ca­tion af­ter giv­ing it a green light … ...